25 XP   0   0   10

BRAIN Biotech AG
Buy, Hold or Sell?

Let's analyse BRAIN Biotech AG together

PenkeI guess you are interested in BRAIN Biotech AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BRAIN Biotech AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BRAIN Biotech AG

I send you an email if I find something interesting about BRAIN Biotech AG.

Quick analysis of BRAIN Biotech AG (30 sec.)










What can you expect buying and holding a share of BRAIN Biotech AG? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.94
Expected worth in 1 year
€0.42
How sure are you?
24.3%

+ What do you gain per year?

Total Gains per Share
€-0.51
Return On Investment
-17.8%

For what price can you sell your share?

Current Price per Share
€2.88
Expected price per share
€2.51 - €3
How sure are you?
50%

1. Valuation of BRAIN Biotech AG (5 min.)




Live pricePrice per Share (EOD)

€2.88

Intrinsic Value Per Share

€-2.56 - €-3.00

Total Value Per Share

€-1.62 - €-2.06

2. Growth of BRAIN Biotech AG (5 min.)




Is BRAIN Biotech AG growing?

Current yearPrevious yearGrowGrow %
How rich?$21.9m$35.7m-$9.5m-36.6%

How much money is BRAIN Biotech AG making?

Current yearPrevious yearGrowGrow %
Making money-$2.2m-$1.7m-$485.2k-21.9%
Net Profit Margin-15.4%-12.3%--

How much money comes from the company's main activities?

3. Financial Health of BRAIN Biotech AG (5 min.)




4. Comparing to competitors in the Specialty Chemicals industry (5 min.)




  Industry Rankings (Specialty Chemicals)  

What can you expect buying and holding a share of BRAIN Biotech AG? (5 min.)

Welcome investor! BRAIN Biotech AG's management wants to use your money to grow the business. In return you get a share of BRAIN Biotech AG.

What can you expect buying and holding a share of BRAIN Biotech AG?

First you should know what it really means to hold a share of BRAIN Biotech AG. And how you can make/lose money.

Speculation

The Price per Share of BRAIN Biotech AG is €2.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BRAIN Biotech AG.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BRAIN Biotech AG, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.94. Based on the TTM, the Book Value Change Per Share is €-0.13 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BRAIN Biotech AG.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.13-4.5%-0.10-3.6%-0.08-2.9%-0.10-3.5%-0.11-3.7%
Usd Book Value Change Per Share-0.12-4.3%-0.14-4.8%-0.10-3.6%-0.02-0.8%0.030.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.12-4.3%-0.14-4.8%-0.10-3.6%-0.02-0.8%0.030.9%
Usd Price Per Share3.92-4.68-7.21-8.32-10.26-
Price to Earnings Ratio-7.56--11.76--331.70--79.22--57.27-
Price-to-Total Gains Ratio-31.59--43.21--24.08--8.76--21.20-
Price to Book Ratio3.90-3.89-4.40-7.01-7.69-
Price-to-Total Gains Ratio-31.59--43.21--24.08--8.76--21.20-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.081312
Number of shares324
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.14-0.02
Usd Total Gains Per Share-0.14-0.02
Gains per Quarter (324 shares)-44.47-7.03
Gains per Year (324 shares)-177.88-28.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-178-1880-28-38
20-356-3660-56-66
30-534-5440-84-94
40-712-7220-113-122
50-889-9000-141-150
60-1067-10780-169-178
70-1245-12560-197-206
80-1423-14340-225-234
90-1601-16120-253-262
100-1779-17900-281-290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.036.00.02.7%1.036.00.02.7%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%5.015.00.025.0%9.025.03.024.3%9.025.03.024.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.037.00.0%0.00.037.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%5.015.00.025.0%9.025.03.024.3%9.025.03.024.3%

Fundamentals of BRAIN Biotech AG

About BRAIN Biotech AG

BRAIN Biotech AG engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates in three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes and biocatalysts to produce food and beverages, wound care preparations or lubricants, and production of starch and bioethanol; and microorganisms as the functional biomass for optimized industrial production processes, recycling of the greenhouse gas CO2 as an industrial raw material, and urban and green mining for extraction of precious and rare earth metals. It also provides biocatalysts and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

Fundamental data was last updated by Penke on 2024-04-19 18:21:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of BRAIN Biotech AG.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit BRAIN Biotech AG earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare BRAIN Biotech AG to the Specialty Chemicals industry mean.
  • A Net Profit Margin of -20.8% means that €-0.21 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BRAIN Biotech AG:

  • The MRQ is -20.8%. The company is making a huge loss. -2
  • The TTM is -15.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-20.8%TTM-15.4%-5.4%
TTM-15.4%YOY-12.3%-3.1%
TTM-15.4%5Y-19.5%+4.0%
5Y-19.5%10Y-28.6%+9.1%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.8%3.8%-24.6%
TTM-15.4%4.4%-19.8%
YOY-12.3%6.5%-18.8%
5Y-19.5%6.0%-25.5%
10Y-28.6%6.0%-34.6%
1.1.2. Return on Assets

Shows how efficient BRAIN Biotech AG is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BRAIN Biotech AG to the Specialty Chemicals industry mean.
  • -4.0% Return on Assets means that BRAIN Biotech AG generated €-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BRAIN Biotech AG:

  • The MRQ is -4.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.0%TTM-3.0%-1.0%
TTM-3.0%YOY-2.1%-0.9%
TTM-3.0%5Y-2.9%-0.1%
5Y-2.9%10Y-3.5%+0.6%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.0%1.5%-5.5%
TTM-3.0%1.6%-4.6%
YOY-2.1%2.5%-4.6%
5Y-2.9%2.2%-5.1%
10Y-3.5%2.4%-5.9%
1.1.3. Return on Equity

Shows how efficient BRAIN Biotech AG is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BRAIN Biotech AG to the Specialty Chemicals industry mean.
  • -13.7% Return on Equity means BRAIN Biotech AG generated €-0.14 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BRAIN Biotech AG:

  • The MRQ is -13.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.7%TTM-9.4%-4.3%
TTM-9.4%YOY-5.8%-3.7%
TTM-9.4%5Y-11.0%+1.6%
5Y-11.0%10Y-10.7%-0.3%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.7%2.9%-16.6%
TTM-9.4%3.1%-12.5%
YOY-5.8%4.7%-10.5%
5Y-11.0%4.3%-15.3%
10Y-10.7%4.4%-15.1%

1.2. Operating Efficiency of BRAIN Biotech AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient BRAIN Biotech AG is operating .

  • Measures how much profit BRAIN Biotech AG makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BRAIN Biotech AG to the Specialty Chemicals industry mean.
  • An Operating Margin of -17.4% means the company generated €-0.17  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BRAIN Biotech AG:

  • The MRQ is -17.4%. The company is operating very inefficient. -2
  • The TTM is -12.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-17.4%TTM-12.4%-5.0%
TTM-12.4%YOY-10.5%-1.8%
TTM-12.4%5Y-18.4%+6.0%
5Y-18.4%10Y-26.9%+8.5%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.4%7.5%-24.9%
TTM-12.4%5.7%-18.1%
YOY-10.5%8.4%-18.9%
5Y-18.4%8.4%-26.8%
10Y-26.9%8.2%-35.1%
1.2.2. Operating Ratio

Measures how efficient BRAIN Biotech AG is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • An Operation Ratio of 1.17 means that the operating costs are €1.17 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of BRAIN Biotech AG:

  • The MRQ is 1.172. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.110. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.172TTM1.110+0.062
TTM1.110YOY1.132-0.022
TTM1.1105Y1.169-0.059
5Y1.16910Y1.271-0.102
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1721.533-0.361
TTM1.1101.543-0.433
YOY1.1321.434-0.302
5Y1.1691.453-0.284
10Y1.2711.295-0.024

1.3. Liquidity of BRAIN Biotech AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if BRAIN Biotech AG is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A Current Ratio of 1.64 means the company has €1.64 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of BRAIN Biotech AG:

  • The MRQ is 1.644. The company is able to pay all its short-term debts. +1
  • The TTM is 1.509. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.644TTM1.509+0.134
TTM1.509YOY1.843-0.334
TTM1.5095Y2.202-0.692
5Y2.20210Y2.662-0.461
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6441.816-0.172
TTM1.5091.886-0.377
YOY1.8431.895-0.052
5Y2.2021.919+0.283
10Y2.6621.816+0.846
1.3.2. Quick Ratio

Measures if BRAIN Biotech AG is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BRAIN Biotech AG to the Specialty Chemicals industry mean.
  • A Quick Ratio of 0.00 means the company can pay off €0.00 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BRAIN Biotech AG:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.526-0.526
TTM0.526YOY0.851-0.325
TTM0.5265Y0.821-0.294
5Y0.82110Y1.172-0.351
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.809-0.809
TTM0.5260.844-0.318
YOY0.8510.926-0.075
5Y0.8211.026-0.205
10Y1.1721.035+0.137

1.4. Solvency of BRAIN Biotech AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of BRAIN Biotech AG assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BRAIN Biotech AG to Specialty Chemicals industry mean.
  • A Debt to Asset Ratio of 0.69 means that BRAIN Biotech AG assets are financed with 69.2% credit (debt) and the remaining percentage (100% - 69.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BRAIN Biotech AG:

  • The MRQ is 0.692. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.653. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.692TTM0.653+0.039
TTM0.653YOY0.573+0.081
TTM0.6535Y0.630+0.023
5Y0.63010Y0.535+0.095
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6920.425+0.267
TTM0.6530.422+0.231
YOY0.5730.424+0.149
5Y0.6300.432+0.198
10Y0.5350.439+0.096
1.4.2. Debt to Equity Ratio

Measures if BRAIN Biotech AG is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BRAIN Biotech AG to the Specialty Chemicals industry mean.
  • A Debt to Equity ratio of 239.0% means that company has €2.39 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BRAIN Biotech AG:

  • The MRQ is 2.390. The company is just not able to pay all its debts with equity.
  • The TTM is 2.074. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.390TTM2.074+0.316
TTM2.074YOY1.564+0.510
TTM2.0745Y2.371-0.296
5Y2.37110Y1.855+0.516
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3900.758+1.632
TTM2.0740.751+1.323
YOY1.5640.738+0.826
5Y2.3710.804+1.567
10Y1.8550.855+1.000

2. Market Valuation of BRAIN Biotech AG

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings BRAIN Biotech AG generates.

  • Above 15 is considered overpriced but always compare BRAIN Biotech AG to the Specialty Chemicals industry mean.
  • A PE ratio of -7.56 means the investor is paying €-7.56 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BRAIN Biotech AG:

  • The EOD is -5.947. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.558. Based on the earnings, the company is expensive. -2
  • The TTM is -11.756. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.947MRQ-7.558+1.611
MRQ-7.558TTM-11.756+4.198
TTM-11.756YOY-331.699+319.943
TTM-11.7565Y-79.215+67.460
5Y-79.21510Y-57.271-21.944
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD-5.94715.618-21.565
MRQ-7.55814.727-22.285
TTM-11.75615.895-27.651
YOY-331.69917.505-349.204
5Y-79.21519.631-98.846
10Y-57.27123.194-80.465
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BRAIN Biotech AG:

  • The EOD is -5.943. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.552. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.371. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.943MRQ-7.552+1.609
MRQ-7.552TTM-6.371-1.181
TTM-6.371YOY333.260-339.631
TTM-6.3715Y48.188-54.559
5Y48.18810Y-32.113+80.301
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD-5.9434.927-10.870
MRQ-7.5524.125-11.677
TTM-6.3712.133-8.504
YOY333.260-2.468+335.728
5Y48.1882.881+45.307
10Y-32.1133.160-35.273
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of BRAIN Biotech AG is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A PB ratio of 3.90 means the investor is paying €3.90 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of BRAIN Biotech AG:

  • The EOD is 3.072. Based on the equity, the company is fair priced.
  • The MRQ is 3.904. Based on the equity, the company is fair priced.
  • The TTM is 3.894. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.072MRQ3.904-0.832
MRQ3.904TTM3.894+0.010
TTM3.894YOY4.396-0.502
TTM3.8945Y7.015-3.121
5Y7.01510Y7.692-0.677
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD3.0721.737+1.335
MRQ3.9041.804+2.100
TTM3.8941.845+2.049
YOY4.3962.318+2.078
5Y7.0152.394+4.621
10Y7.6922.693+4.999
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BRAIN Biotech AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.116-0.128+11%-0.096-17%-0.020-82%0.025-557%
Book Value Per Share--0.9381.121-16%1.532-39%1.222-23%1.137-18%
Current Ratio--1.6441.509+9%1.843-11%2.202-25%2.662-38%
Debt To Asset Ratio--0.6920.653+6%0.573+21%0.630+10%0.535+29%
Debt To Equity Ratio--2.3902.074+15%1.564+53%2.371+1%1.855+29%
Dividend Per Share----0%-0%-0%-0%
Eps---0.121-0.096-21%-0.077-36%-0.095-22%-0.100-18%
Free Cash Flow Per Share---0.121-0.071-42%-0.038-68%-0.074-39%-0.075-38%
Free Cash Flow To Equity Per Share---0.022-0.064+192%-0.034+56%-0.016-26%0.031-171%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---3.001--------
Intrinsic Value_10Y_min---2.561--------
Intrinsic Value_1Y_max---0.210--------
Intrinsic Value_1Y_min---0.206--------
Intrinsic Value_3Y_max---0.701--------
Intrinsic Value_3Y_min---0.667--------
Intrinsic Value_5Y_max---1.274--------
Intrinsic Value_5Y_min---1.177--------
Market Cap62920800.000-27%79961850.00095473575.000-16%147197531.250-46%169962626.250-53%209437811.149-62%
Net Profit Margin---0.208-0.154-26%-0.123-41%-0.195-6%-0.286+37%
Operating Margin---0.174-0.124-29%-0.105-39%-0.184+6%-0.269+55%
Operating Ratio--1.1721.110+6%1.132+3%1.169+0%1.271-8%
Pb Ratio3.072-27%3.9043.894+0%4.396-11%7.015-44%7.692-49%
Pe Ratio-5.947+21%-7.558-11.756+56%-331.699+4289%-79.215+948%-57.271+658%
Price Per Share2.880-27%3.6604.370-16%6.738-46%7.780-53%9.586-62%
Price To Free Cash Flow Ratio-5.943+21%-7.552-6.371-16%333.260-102%48.188-116%-32.113+325%
Price To Total Gains Ratio-24.860+21%-31.593-43.207+37%-24.085-24%-8.757-72%-21.203-33%
Quick Ratio---0.526-100%0.851-100%0.821-100%1.172-100%
Return On Assets---0.040-0.030-26%-0.021-48%-0.029-27%-0.035-13%
Return On Equity---0.137-0.094-31%-0.058-58%-0.110-20%-0.107-22%
Total Gains Per Share---0.116-0.128+11%-0.096-17%-0.020-82%0.025-557%
Usd Book Value--21914761.70026201316.050-16%35799656.425-39%28556807.890-23%26581784.895-18%
Usd Book Value Change Per Share---0.124-0.137+11%-0.103-17%-0.022-82%0.027-557%
Usd Book Value Per Share--1.0031.199-16%1.639-39%1.307-23%1.217-18%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.130-0.103-21%-0.083-36%-0.101-22%-0.107-18%
Usd Free Cash Flow---2832025.300-1654600.350-42%-892296.600-68%-1732596.060-39%-1761325.882-38%
Usd Free Cash Flow Per Share---0.130-0.076-42%-0.041-68%-0.079-39%-0.081-38%
Usd Free Cash Flow To Equity Per Share---0.024-0.069+192%-0.037+56%-0.017-26%0.033-171%
Usd Market Cap67318963.920-27%85551183.315102147177.893-16%157486638.684-46%181843013.825-53%224077514.148-62%
Usd Price Per Share3.081-27%3.9164.675-16%7.208-46%8.323-53%10.256-62%
Usd Profit---2829885.500-2214693.000-22%-1729493.350-39%-2189015.400-23%-2321984.076-18%
Usd Revenue--13618757.10014542615.750-6%14183129.350-4%11945861.460+14%9479467.632+44%
Usd Total Gains Per Share---0.124-0.137+11%-0.103-17%-0.022-82%0.027-557%
 EOD+3 -5MRQTTM+10 -23YOY+5 -285Y+5 -2810Y+6 -27

3.2. Fundamental Score

Let's check the fundamental score of BRAIN Biotech AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.947
Price to Book Ratio (EOD)Between0-13.072
Net Profit Margin (MRQ)Greater than0-0.208
Operating Margin (MRQ)Greater than0-0.174
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.644
Debt to Asset Ratio (MRQ)Less than10.692
Debt to Equity Ratio (MRQ)Less than12.390
Return on Equity (MRQ)Greater than0.15-0.137
Return on Assets (MRQ)Greater than0.05-0.040
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of BRAIN Biotech AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.665
Ma 20Greater thanMa 503.056
Ma 50Greater thanMa 1003.516
Ma 100Greater thanMa 2003.580
OpenGreater thanClose2.830
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets66,471
Total Liabilities45,988
Total Stockholder Equity19,240
 As reported
Total Liabilities 45,988
Total Stockholder Equity+ 19,240
Total Assets = 66,471

Assets

Total Assets66,471
Total Current Assets22,074
Long-term Assets44,398
Total Current Assets
Total Current Assets  (as reported)22,074
Total Current Assets  (calculated)0
+/- 22,074
Long-term Assets
Long-term Assets  (as reported)44,398
Long-term Assets  (calculated)0
+/- 44,398

Liabilities & Shareholders' Equity

Total Current Liabilities13,428
Long-term Liabilities32,560
Total Stockholder Equity19,240
Total Current Liabilities
Total Current Liabilities  (as reported)13,428
Total Current Liabilities  (calculated)0
+/- 13,428
Long-term Liabilities
Long-term Liabilities  (as reported)32,560
Long-term Liabilities  (calculated)0
+/- 32,560
Total Stockholder Equity
Total Stockholder Equity (as reported)19,240
Total Stockholder Equity (calculated)0
+/- 19,240
Other
Common Stock Shares Outstanding 21,847
Liabilities and Stockholders Equity 65,228
Net Working Capital 8,646



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
0
0
0
30,407
30,342
50,691
48,059
47,512
45,694
43,569
41,279
68,504
66,274
72,183
78,837
74,464
72,618
69,700
65,169
66,124
70,410
64,806
75,736
72,150
67,367
67,145
60,089
77,737
76,237
81,631
77,903
77,992
75,533
74,511
69,484
70,937
66,471
66,47170,93769,48474,51175,53377,99277,90381,63176,23777,73760,08967,14567,36772,15075,73664,80670,41066,12465,16969,70072,61874,46478,83772,18366,27468,50441,27943,56945,69447,51248,05950,69130,34230,407000
   > Total Current Assets 
0
0
0
15,071
15,006
35,586
32,962
32,001
30,317
28,294
25,826
53,557
51,371
44,358
46,772
41,016
38,888
34,426
30,913
30,957
28,118
21,972
34,906
33,083
29,177
26,234
20,146
39,114
36,453
35,011
31,453
30,384
29,090
28,012
23,210
25,476
22,074
22,07425,47623,21028,01229,09030,38431,45335,01136,45339,11420,14626,23429,17733,08334,90621,97228,11830,95730,91334,42638,88841,01646,77244,35851,37153,55725,82628,29430,31732,00132,96235,58615,00615,071000
       Cash And Cash Equivalents 
0
0
0
3,180
0
8,509
0
8,261
4,470
10,953
8,140
38,954
39,463
24,726
25,992
25,539
23,823
18,504
15,402
15,160
13,249
6,386
0
18,943
0
11,952
0
24,545
0
16,440
0
8,443
10,762
9,156
5,321
5,352
0
05,3525,3219,15610,7628,443016,440024,545011,952018,94306,38613,24915,16015,40218,50423,82325,53925,99224,72639,46338,9548,14010,9534,4708,26108,50903,180000
       Short-term Investments 
0
0
0
300
0
15,000
0
10,400
0
4,348
0
86
0
4,129
0
260
38,888
200
0
63
0
212
0
103
0
344
0
105
0
215
0
362
0
680
0
55
0
0550680036202150105034401030212063020038,88826004,12908604,348010,400015,0000300000
       Net Receivables 
0
0
0
0
0
0
0
0
0
5,760
0
6,844
0
5,829
0
6,738
0
6,085
0
7,102
0
6,789
0
6,566
0
6,193
0
6,953
0
8,542
0
11,381
0
7,244
0
9,864
0
09,86407,244011,38108,54206,95306,19306,56606,78907,10206,08506,73805,82906,84405,760000000000
       Other Current Assets 
0
0
0
5,075
15,006
5,672
32,962
6,218
30,317
6,342
25,826
7,328
51,371
7,230
46,772
7,184
38,888
7,305
30,913
7,808
28,118
7,637
34,906
7,073
29,177
6,997
20,146
7,453
36,453
898
31,453
574
29,090
1,266
17,889
479
0
047917,8891,26629,09057431,45389836,4537,45320,1466,99729,1777,07334,9067,63728,1187,80830,9137,30538,8887,18446,7727,23051,3717,32825,8266,34230,3176,21832,9625,67215,0065,075000
   > Long-term Assets 
0
0
0
15,336
15,336
15,105
15,097
15,511
15,377
15,275
15,453
14,947
14,903
27,825
32,065
33,448
33,730
35,274
34,256
35,167
42,292
42,834
40,830
39,067
38,190
40,911
39,943
38,623
39,784
46,620
46,450
47,608
46,443
46,499
46,274
45,462
44,398
44,39845,46246,27446,49946,44347,60846,45046,62039,78438,62339,94340,91138,19039,06740,83042,83442,29235,16734,25635,27433,73033,44832,06527,82514,90314,94715,45315,27515,37715,51115,09715,10515,33615,336000
       Property Plant Equipment 
0
0
0
6,878
0
6,893
0
7,095
0
7,126
0
7,590
0
11,656
0
12,042
0
14,444
0
17,144
0
24,966
0
24,469
0
24,773
0
24,291
0
26,536
0
28,738
0
28,606
0
28,720
0
028,720028,606028,738026,536024,291024,773024,469024,966017,144014,444012,042011,65607,59007,12607,09506,89306,878000
       Goodwill 
0
0
0
2,818
0
0
0
2,817
0
0
0
2,671
0
0
0
6,365
0
0
0
4,586
0
0
0
4,484
0
0
0
4,725
0
0
0
6,606
0
0
0
6,666
0
06,6660006,6060004,7250004,4840004,5860006,3650002,6710002,8170002,818000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
168
0
166
0
166
0
1,984
33,730
1,734
0
1,438
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,43801,73433,7301,984016601660168000000000
       Intangible Assets 
0
0
0
5,217
0
0
0
4,930
0
7,479
0
4,416
0
15,777
0
12,711
0
18,753
0
11,208
0
15,122
0
8,787
0
14,466
0
8,806
0
18,349
0
10,159
0
15,835
0
8,549
0
08,549015,835010,159018,34908,806014,46608,787015,122011,208018,753012,711015,77704,41607,47904,9300005,217000
       Other Assets 
0
0
0
0
0
0
0
0
15,377
502
15,453
103
14,902
226
32,065
347
33,730
343
34,255
790
42,292
813
40,830
329
38,190
335
39,943
251
39,784
266
46,450
169
46,443
155
46,274
-1
-1
-1-146,27415546,44316946,45026639,78425139,94333538,19032940,83081342,29279034,25534333,73034732,06522614,90210315,45350215,37700000000
> Total Liabilities 
0
0
0
24,652
25,020
18,865
18,763
20,586
21,419
20,374
19,695
21,142
21,254
39,970
46,152
43,825
43,269
42,947
42,325
49,032
55,183
51,925
49,827
46,007
44,263
41,136
35,947
35,910
36,147
46,411
45,222
43,744
43,839
44,645
44,889
47,923
45,988
45,98847,92344,88944,64543,83943,74445,22246,41136,14735,91035,94741,13644,26346,00749,82751,92555,18349,03242,32542,94743,26943,82546,15239,97021,25421,14219,69520,37421,41920,58618,76318,86525,02024,652000
   > Total Current Liabilities 
0
0
0
7,727
7,595
6,823
6,378
10,413
9,642
8,778
7,328
8,425
8,533
12,951
11,798
10,973
10,545
11,822
11,121
14,873
14,527
12,725
11,283
12,357
10,826
14,074
9,407
11,335
11,173
13,465
17,020
21,388
19,340
20,402
14,845
17,479
13,428
13,42817,47914,84520,40219,34021,38817,02013,46511,17311,3359,40714,07410,82612,35711,28312,72514,52714,87311,12111,82210,54510,97311,79812,9518,5338,4257,3288,7789,64210,4136,3786,8237,5957,727000
       Short-term Debt 
0
0
0
2,106
0
1,040
0
3,449
0
1,695
0
1,514
0
5,088
0
2,442
0
2,943
0
3,603
0
2,873
0
3,277
0
0
0
2,643
0
0
0
3,037
0
10,985
0
4,659
0
04,659010,98503,0370002,6430003,27702,87303,60302,94302,44205,08801,51401,69503,44901,04002,106000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
998
0
5,088
0
1,378
0
0
0
1,220
0
0
0
0
0
0
0
1,567
0
0
0
1,765
0
0
0
3,218
0
03,2180001,7650001,56700000001,2200001,37805,088099800000000000
       Accounts payable 
0
0
0
3,082
0
3,141
0
2,862
0
2,441
0
2,433
0
3,311
0
2,872
0
3,924
0
4,428
0
3,592
0
3,171
0
3,346
0
3,831
0
5,629
0
6,754
0
4,220
0
5,617
0
05,61704,22006,75405,62903,83103,34603,17103,59204,42803,92402,87203,31102,43302,44102,86203,14103,082000
       Other Current Liabilities 
0
0
0
2,539
7,595
2,642
6,378
4,103
9,642
4,642
7,328
4,478
8,533
4,552
11,798
5,659
10,545
4,955
11,121
6,842
14,527
6,260
11,283
5,909
10,826
10,728
9,407
4,319
11,173
7,836
17,020
11,597
19,340
3,295
14,845
1,304
0
01,30414,8453,29519,34011,59717,0207,83611,1734,3199,40710,72810,8265,90911,2836,26014,5276,84211,1214,95510,5455,65911,7984,5528,5334,4787,3284,6429,6424,1036,3782,6427,5952,539000
   > Long-term Liabilities 
0
0
0
16,924
17,425
12,042
12,385
10,173
11,777
11,596
12,367
12,717
12,721
27,019
34,354
32,852
32,724
31,125
31,204
34,159
40,656
39,200
38,544
33,650
33,437
27,062
26,540
24,575
24,974
32,946
28,202
22,356
24,499
24,243
30,044
30,444
32,560
32,56030,44430,04424,24324,49922,35628,20232,94624,97424,57526,54027,06233,43733,65038,54439,20040,65634,15931,20431,12532,72432,85234,35427,01912,72112,71712,36711,59611,77710,17312,38512,04217,42516,924000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,219
0
17,669
0
24,717
0
15,435
0
17,674
0
0
0
00017,674015,435024,717017,669020,2190000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
11,777
11,596
12,367
10,552
12,721
27,020
34,354
27,265
32,724
31,125
31,204
28,781
40,656
39,200
38,544
22,894
33,437
27,062
26,540
15,515
24,974
32,946
28,202
14,323
24,499
24,243
30,044
0
0
0030,04424,24324,49914,32328,20232,94624,97415,51526,54027,06233,43722,89438,54439,20040,65628,78131,20431,12532,72427,26534,35427,02012,72110,55212,36711,59611,77700000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
70
0
0
0
251
0
0
0
216
0
0
0
113
0
0
0
86
0
0
0
0
0
0
0
0
0
000000000860001130002160002510007000000000000
> Total Stockholder Equity
0
0
0
5,451
5,322
31,585
29,054
26,680
24,029
22,970
21,359
47,180
44,837
29,700
30,173
25,755
24,465
21,656
17,746
12,234
10,370
7,831
20,859
20,785
17,746
20,132
24,142
38,783
37,046
30,282
27,743
29,638
27,084
25,077
23,322
21,771
19,240
19,24021,77123,32225,07727,08429,63827,74330,28237,04638,78324,14220,13217,74620,78520,8597,83110,37012,23417,74621,65624,46525,75530,17329,70044,83747,18021,35922,97024,02926,68029,05431,5855,3225,451000
   Common Stock
0
0
0
12,726
0
16,414
0
16,414
24,275
16,414
21,584
18,056
45,019
18,056
32,685
18,056
29,349
18,056
22,843
18,056
15,227
18,056
25,909
19,861
23,104
19,861
24,142
21,847
40,090
21,847
32,681
21,847
31,694
21,847
23,322
21,847
0
021,84723,32221,84731,69421,84732,68121,84740,09021,84724,14219,86123,10419,86125,90918,05615,22718,05622,84318,05629,34918,05632,68518,05645,01918,05621,58416,41424,27516,414016,414012,726000
   Retained Earnings Total Equity0000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-5,621
0
0
0
-6,225
0
0
0
-6,935
0
0
0
-7,918
0
0
0
-8,838
0
0
0
-10,436
0
0
0
0
0
0
0
0
0
164
0
627
0
06270164000000000-10,436000-8,838000-7,918000-6,935000-6,225000-5,621000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
64,961
0
78,386
0
78,580
0
95,890
0
91,041
0
92,660
0
93,060
0
0
0
00093,060092,660091,041095,890078,580078,386064,961000000000000000000000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
21,785
0
44,672
0
54,620
0
49,956
0
83,795
0
64,047
0
71,406
0
63,563
0
73,664
15,227
65,113
25,909
88,857
23,104
79,055
24,142
96,445
37,046
91,899
27,743
92,988
-4,610
93,060
0
93,458
0
093,458093,060-4,61092,98827,74391,89937,04696,44524,14279,05523,10488,85725,90965,11315,22773,664063,563071,406064,047083,795049,956054,620044,672021,785000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-09-30)

Gross Profit (+$)
totalRevenue55,335
Cost of Revenue-25,213
Gross Profit30,12230,122
 
Operating Income (+$)
Gross Profit30,122
Operating Expense-35,704
Operating Income-5,480-5,582
 
Operating Expense (+$)
Research Development4,979
Selling General Administrative2,573
Selling And Marketing Expenses2,807
Operating Expense35,70410,359
 
Net Interest Income (+$)
Interest Income4
Interest Expense-858
Other Finance Cost-59
Net Interest Income-913
 
Pretax Income (+$)
Operating Income-5,480
Net Interest Income-913
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-7,489-3,471
EBIT - interestExpense = -7,929
-7,654
-7,421
Interest Expense858
Earnings Before Interest and Taxes (EBIT)-7,071-6,631
Earnings Before Interest and Taxes (EBITDA)-2,417
 
After tax Income (+$)
Income Before Tax-7,489
Tax Provision-625
Net Income From Continuing Ops-8,114-8,114
Net Income-8,279
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses60,917
Total Other Income/Expenses Net-2,009913
 

Technical Analysis of BRAIN Biotech AG
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BRAIN Biotech AG. The general trend of BRAIN Biotech AG is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BRAIN Biotech AG's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BRAIN Biotech AG.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: < < 3.

The bearish price targets are: 2.51.

Tweet this
BRAIN Biotech AG Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BRAIN Biotech AG. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BRAIN Biotech AG Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BRAIN Biotech AG. The current macd is -0.20977275.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the BRAIN Biotech AG price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for BRAIN Biotech AG. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the BRAIN Biotech AG price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
BRAIN Biotech AG Daily Moving Average Convergence/Divergence (MACD) ChartBRAIN Biotech AG Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BRAIN Biotech AG. The current adx is 54.88.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell BRAIN Biotech AG shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
BRAIN Biotech AG Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BRAIN Biotech AG. The current sar is 3.22944716.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BRAIN Biotech AG Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BRAIN Biotech AG. The current rsi is 33.67. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
BRAIN Biotech AG Daily Relative Strength Index (RSI) ChartBRAIN Biotech AG Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BRAIN Biotech AG. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the BRAIN Biotech AG price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
BRAIN Biotech AG Daily Stochastic Oscillator ChartBRAIN Biotech AG Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BRAIN Biotech AG. The current cci is -81.34296118.

BRAIN Biotech AG Daily Commodity Channel Index (CCI) ChartBRAIN Biotech AG Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BRAIN Biotech AG. The current cmo is -26.09439329.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
BRAIN Biotech AG Daily Chande Momentum Oscillator (CMO) ChartBRAIN Biotech AG Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BRAIN Biotech AG. The current willr is -54.32098765.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that BRAIN Biotech AG is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BRAIN Biotech AG Daily Williams %R ChartBRAIN Biotech AG Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BRAIN Biotech AG.

BRAIN Biotech AG Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BRAIN Biotech AG. The current atr is 0.21094736.

BRAIN Biotech AG Daily Average True Range (ATR) ChartBRAIN Biotech AG Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BRAIN Biotech AG. The current obv is -512,696.

BRAIN Biotech AG Daily On-Balance Volume (OBV) ChartBRAIN Biotech AG Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BRAIN Biotech AG. The current mfi is 19.49.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
BRAIN Biotech AG Daily Money Flow Index (MFI) ChartBRAIN Biotech AG Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BRAIN Biotech AG.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-26ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

BRAIN Biotech AG Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BRAIN Biotech AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.665
Ma 20Greater thanMa 503.056
Ma 50Greater thanMa 1003.516
Ma 100Greater thanMa 2003.580
OpenGreater thanClose2.830
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of BRAIN Biotech AG with someone you think should read this too:
  • Are you bullish or bearish on BRAIN Biotech AG? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BRAIN Biotech AG? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BRAIN Biotech AG

I send you an email if I find something interesting about BRAIN Biotech AG.


Comments

How you think about this?

Leave a comment

Stay informed about BRAIN Biotech AG.

Receive notifications about BRAIN Biotech AG in your mailbox!